Brought to you by:
Gore announces first commercial implant of Gore Tag thoracic branch endoprosthesis in Canada
Gore has announced the first commercial use of the Gore Tag thoracic branch endoprosthesis (TBE) in Canada. The news came as Canadian government health authority Health Canada approved the first-of-its-kind endovascular device, which is indicated to treat lesions of the…
US FDA approves expanded indication for Gore Excluder conformable device
Gore has announced US Food and Drug Administration (FDA) approval of an expanded indication for the Gore Excluder conformable abdominal aortic aneurysm (AAA) endoprosthesis. The device is now indicated for patients with aortic neck angulation ≤90° and a minimum length…
Viabahn VBX stent graft receives FDA approval
Gore has announced recent Food and Drug Administration (FDA) approval of a lower profile Viabahn VBX balloon expandable endoprosthesis (VBX stent graft) for the treatment of complex iliac occlusive disease. “Our team is pleased to be the first commercial implanter of…
Gore receives FDA approval for breakthrough endovascular device in complex aortic aneurysms
Gore has announced Food and Drug Administration (FDA) approval for the Gore Excluder thoracoabdominal branch endoprosthesis (TAMBE), which the company states is the first off-the-shelf endovascular solution for the treatment of complex aneurysmal disease involving the visceral aorta. A press…
First patients enrolled in VBX FORWARD clinical study
Gore has announced that the first patients have been enrolled in the Gore VBX FORWARD clinical study, a global prospective, multicenter, randomized controlled trial to compare the Gore Viabahn VBX balloon expandable endoprosthesis (VBX stent graft) to bare metal stenting for patients…
First patient treated in ARISE II study of ascending stent graft
Gore has announced the first patient implantation of the company’s ascending stent graft in the ARISE II trial, describing this as an exciting step in the development of treatments for pathologies involving the ascending aorta using endovascular repair rather than…
First US patient enrolled in Gore Viafort vascular stent pivotal study
W L Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, randomized, multicenter, single-arm study with five-year follow-up to evaluate the investigational Gore Viafort vascular stent for the treatment of symptomatic inferior…
Gore completes first-in-human implants of Viafort vascular stent
W. L. Gore today announced the first implants of its investigational Gore Viafort vascular stent as part of a recently initiated pivotal clinical study for the treatment of inferior vena cava (IVC) occlusive disease with or without iliofemoral vein involvement. The…
Why 25 years of patient-centered innovation really matters
This advertorial is sponsored by Gore. One mainstay endovascular aneurysm repair (EVAR) device is celebrating not just a quarter century of being commercially available, but the innovation it has inspired along the way. Michel Makaroun, MD, and Willy Davison, PhD,…
Gore acquires InnAVasc Medical
Gore has announced the acquisition of InnAVasc Medical, a privately held medical technology company focused on advancing care for patients with end-stage renal disease who utilise graft circuits for dialysis treatment. Jeffrey Lawson, MD, PhD, and Shawn Gage, PA-C, of…